Ontario Clinical Oncology Group (ocog)
Clinical trials sponsored by Ontario Clinical Oncology Group (ocog), explained in plain language.
-
Genetic test may spare thousands of women from unnecessary radiation
Disease control Recruiting nowThis study looks at whether women over 45 with a low-risk type of early breast cancer (DCIS) can avoid radiation after breast-conserving surgery. A genetic test helps identify those with a very low chance of the cancer coming back. The goal is to see if skipping radiation is safe…
Sponsor: Ontario Clinical Oncology Group (OCOG) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
One-Week radiation after breast cancer surgery could be just as good, with better looks
Disease control Recruiting nowThis study compares two types of radiation therapy for women with early-stage breast cancer who have had a lumpectomy. One group receives radiation to the whole breast, the other only to the area where the cancer was removed. Both treatments are given once a day for about one wee…
Phase: PHASE3 • Sponsor: Ontario Clinical Oncology Group (OCOG) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Radiation-Free breast cancer treatment? new trial tests skipping it after chemo success
Disease control Recruiting nowThis study is testing whether women with early-stage breast cancer that has not spread to lymph nodes can safely skip radiation therapy after a lumpectomy, if their tumor completely disappeared with chemotherapy. The trial will enroll 352 women and follow them for cancer recurren…
Sponsor: Ontario Clinical Oncology Group (OCOG) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New dosing strategy aims to keep myeloma patients out of the hospital
Disease control Recruiting nowThis study tests a new way of giving the drug elranatamab to people with multiple myeloma that has come back or stopped responding to other treatments. The goal is to see if giving the drug less often and outside the hospital can reduce side effects and hospital stays. About 40 a…
Phase: PHASE2 • Sponsor: Ontario Clinical Oncology Group (OCOG) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New trial: can hormone pills boost targeted cancer therapy?
Disease control Recruiting nowThis study is for men whose prostate cancer has come back in a few spots after radiation, but is still hormone-sensitive. Researchers want to see if adding a 12-month course of hormone therapy (ELIGARD) to targeted treatments like radiation or surgery helps keep the cancer from g…
Phase: PHASE2 • Sponsor: Ontario Clinical Oncology Group (OCOG) • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC